News

Andexanet alfa, which is in Phase 3 clinical development in the U.S. and Europe, is designed to reverse the anticoagulant activity of Factor Xa inhibitors, includingEliquis (apixaban). Bristol-Myers

The conjugate is subsequently labeled with indium-111 (111In) and other potential radioisotopes for in vivo diagnostic imaging and treatment of cancers. Panacea Pharmaceuticals COO Steven Fuller said: "Panacea

Truvada was approved by the EMA in 2005 in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults, and is currently the most prescribed

Kathy Niakan, a group leader at the Francis Crick Institute in London, will lead the research and use the CRISPR-Cas9 genome-editing technique in healthy human embryos. The researchers

The company’s vaccines division, Sanofi Pasteur, will use its expertise in developing vaccine for the virus. Sanofi Pasteur has developed vaccines against viruses in the same family as

The company expects to commence phase 1/2 clinical trial in the second quarter of this year. AP32788 is an internally discovered product candidate designed as a targeted therapy

This trial will evaluate the safety and efficacy of SPI-2012 as a treatment for chemotherapy-induced neutropenia in patients with breast cancer, and will serve as the basis for

The trial is testing RGN-259 (Thymosin beta 4), a sterile, preservative-free eye drop developed for patients with dry eye syndrome, neurotrophic keratopathy (NK), and other corneal disorders. The

The application now will be reviewed by the European Commission, which has the authority to approve medicines for the European Union (EU). Bristol-Myers Squibb senior vice president, head